Access cutting-edge non-small cell lung cancer treatment through this clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.
Access non-small cell lung cancer specialists in Atlanta at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-small cell lung cancer treatment provided free
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:1 to treatment in the experimental arm or the control arm. Participant randomization will be stratified by geographical region (North America vs Europe vs ASIA vs Other), NSCLC histology (squamous vs nonsquamous), and actionable genomic alteration (AGA); (epide
Sponsor: ImmunityBio, Inc.
Check if you qualify for this non-small cell lung cancer clinical trial in Atlanta, GA
If you're searching for non-small cell lung cancer treatment options in Atlanta, GA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Atlanta research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.